

Monia Guidi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5468133/publications.pdf>

Version: 2024-02-01

55
papers

1,298
citations

331259

21
h-index

377514

34
g-index

56
all docs

56
docs citations

56
times ranked

1974
citing authors

#	ARTICLE	IF	CITATIONS
1	Parametric Approaches in Population Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 125-141.	1.0	17
2	Parametric and Nonparametric Methods in Population Pharmacokinetics: Experts' Discussion on Use, Strengths, and Limitations. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 158-170.	1.0	9
3	Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, , .	1.3	4
4	Enantiospecific pharmacokinetics of intravenous dexmedetomidine in beagles. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2022, , .	0.6	3
5	Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 353-363.	2.3	5
6	Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer. <i>Pharmaceutics</i> , 2022, 14, 1317.	2.0	3
7	Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2021, 60, 379-390.	1.6	4
8	Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 979-987.	0.8	2
9	Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4455-4460.	1.1	0
10	Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 5012-5019.	3.2	10
11	Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, , .	1.3	2
12	Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: Lessons from the CounterCOVID -imatinib study. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1497-1511.	1.3	8
13	Optimisation of vancomycin exposure in neonates based on the best level of evidence. <i>Pharmacological Research</i> , 2020, 154, 104278.	3.1	25
14	Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses. <i>Clinical Pharmacokinetics</i> , 2020, 59, 371-382.	1.6	8
15	Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 33-44.	1.0	25
16	Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. <i>Aids</i> , 2020, 34, 103-108.	1.0	18
17	The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib. <i>Frontiers in Pharmacology</i> , 2020, 11, 177.	1.6	59
18	A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1642-1653.	1.1	13

#	ARTICLE	IF	CITATIONS
19	Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients. <i>Clinical Therapeutics</i> , 2020, 42, 1302-1316.	1.1	13
20	Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz464.	0.4	7
21	Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma. <i>Cancers</i> , 2020, 12, 931.	1.7	12
22	Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1037-1048.	1.6	5
23	Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00558.	1.1	8
24	Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2690-2697.	1.3	23
25	Methods for Personalised Delivery Rate Computation for IV Administered Anesthetic Propofol. <i>Computational Biology</i> , 2019, , 369-397.	0.1	1
26	Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2022-2032.	1.1	7
27	Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children. <i>Malaria Journal</i> , 2019, 18, 139.	0.8	10
28	Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial. <i>PLoS ONE</i> , 2019, 14, e0210789.	1.1	3
29	Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 939-949.	0.8	2
30	Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz531.	0.4	38
31	Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3413-3422.	1.3	40
32	Robustness analysis of personalised delivery rate computation for IV administered anesthetic. <i>Smart Health</i> , 2018, 9-10, 101-114.	2.0	7
33	Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	32
34	Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1933-1942.	1.3	13
35	Cascaded PID controller for anaesthesia delivery. , 2016, 2016, 533-536.		7
36	Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1521-1533.	1.6	25

#	ARTICLE	IF	CITATIONS
37	Vitamin D Time Profile Based on the Contribution of Non-Genetic and Genetic Factors in HIV-Infected Individuals of European Ancestry. <i>Antiviral Therapy</i> , 2015, 20, 261-269.	0.6	5
38	Erlotinib. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 2-21.	1.0	36
39	Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1259-1272.	1.6	44
40	Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1090-1101.	1.1	50
41	Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2489-2498.	1.3	31
42	High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate. <i>Journal of Chromatography A</i> , 2014, 1369, 52-63.	1.8	26
43	Population pharmacokinetic approach to evaluate the effect of <i>CYP2D6</i> , <i>CYP3A</i> , <i>ABCB1</i> , <i>POR</i> and <i>NR112</i> genotypes on donepezil clearance. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 135-144.	1.1	46
44	Population Pharmacokinetics and Clinical Response for Artemether-Lumefantrine in Pregnant and Nonpregnant Women with Uncomplicated Plasmodium falciparum Malaria in Tanzania. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4583-4592.	1.4	37
45	Population pharmacokinetics of mefloquine, piperazine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients. <i>Malaria Journal</i> , 2013, 12, 235.	0.8	33
46	Population Pharmacokinetic Study of Memantine: Effects of Clinical and Genetic Factors. <i>Clinical Pharmacokinetics</i> , 2013, 52, 211-223.	1.6	41
47	Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1007-1018.	1.1	33
48	Relationship of CYP2D6, CYP3A, POR, and ABCB1 Genotypes With Galantamine Plasma Concentrations. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 270-275.	1.0	27
49	Effect of Single Nucleotide Polymorphisms in Cytochrome P450 Isoenzyme and <i>N-Acetyltransferase 2</i> Genes on the Metabolism of Artemisinin-Based Combination Therapies in Malaria Patients from Cambodia and Tanzania. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 950-958.	1.4	51
50	Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 9-18.	0.7	25
51	Dosage Optimization of Treatments Using Population Pharmacokinetic Modeling and Simulation. <i>Chimia</i> , 2012, 66, 291-295.	0.3	8
52	Spectroscopy of Protonated Peptides Assisted by Infrared Multiple Photon Excitation. <i>Journal of Physical Chemistry A</i> , 2009, 113, 797-799.	1.1	43
53	Conformation-specific infrared and ultraviolet spectroscopy of tyrosine-based protonated dipeptides. <i>Journal of Chemical Physics</i> , 2007, 127, 154322.	1.2	80
54	Conformation-Specific Spectroscopy and Photodissociation of Cold, Protonated Tyrosine and Phenylalanine. <i>Journal of the American Chemical Society</i> , 2007, 129, 11814-11820.	6.6	195

#	ARTICLE	IF	CITATIONS
55	Some Properties of Lysozyme~Lithium Perfluoronanoate Complexes. Biomacromolecules, 2007, 8, 399-405.	2.6	11